KR20060113699A - 치환된 이소퀴놀리논 - Google Patents

치환된 이소퀴놀리논 Download PDF

Info

Publication number
KR20060113699A
KR20060113699A KR1020067008642A KR20067008642A KR20060113699A KR 20060113699 A KR20060113699 A KR 20060113699A KR 1020067008642 A KR1020067008642 A KR 1020067008642A KR 20067008642 A KR20067008642 A KR 20067008642A KR 20060113699 A KR20060113699 A KR 20060113699A
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
hydrogen
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067008642A
Other languages
English (en)
Korean (ko)
Inventor
로버트 엠. 스카보로우
킴 에이. 켄-마귀레
챨스 케이. 말로우
마크 에스. 스미쓰
자오밍 쟁
Original Assignee
포톨라 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포톨라 파마슈티컬스, 인코포레이티드 filed Critical 포톨라 파마슈티컬스, 인코포레이티드
Publication of KR20060113699A publication Critical patent/KR20060113699A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067008642A 2003-10-03 2004-09-29 치환된 이소퀴놀리논 Ceased KR20060113699A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50840203P 2003-10-03 2003-10-03
US60/508,402 2003-10-03

Publications (1)

Publication Number Publication Date
KR20060113699A true KR20060113699A (ko) 2006-11-02

Family

ID=34434908

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067008642A Ceased KR20060113699A (ko) 2003-10-03 2004-09-29 치환된 이소퀴놀리논

Country Status (10)

Country Link
US (1) US7294635B2 (enExample)
EP (1) EP1667989A4 (enExample)
JP (1) JP4879745B2 (enExample)
KR (1) KR20060113699A (enExample)
CN (1) CN1863789B (enExample)
AU (1) AU2004279809B2 (enExample)
CA (1) CA2539882A1 (enExample)
IL (1) IL174445A (enExample)
MX (1) MXPA06003625A (enExample)
WO (1) WO2005035520A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516181A (pt) * 2004-09-29 2008-08-26 Portola Pharm Inc composto e sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, métodos para tratar trombose em um indivìduo e para prevenir a ocorrência de um evento isquêmico secundário
KR20080039405A (ko) * 2005-07-13 2008-05-07 아스트라제네카 아베 신규한 피리딘 유사체
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
KR20090031605A (ko) * 2006-07-04 2009-03-26 아스트라제네카 아베 신규한 피리딘 유사체
KR20090036573A (ko) * 2006-07-04 2009-04-14 아스트라제네카 아베 신규한 피리딘 유사체
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
BRPI0806371A2 (pt) 2007-01-22 2011-09-13 Gtx Inc agentes ligação de receptor nuclear
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
EA020045B1 (ru) 2007-05-02 2014-08-29 Портола Фармасьютиклз, Инк. Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
AR064865A1 (es) * 2007-07-13 2009-04-29 Astrazeneca Ab Derivados de piridina antagonistas de p2y12
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
US9776992B2 (en) * 2014-12-02 2017-10-03 Eli Lilly And Company 1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers
PE20221627A1 (es) 2015-02-16 2022-10-19 Univ Queensland Sulfonilureas y compuestos relacionados y uso de estos
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
JP2021502364A (ja) 2017-11-09 2021-01-28 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847925A (en) * 1971-07-15 1974-11-12 En Nom Collectif Science Et Ci Benzenesulfonyl semicarbazides
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (ja) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド 血小板adp受容体阻害剤
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP4574100B2 (ja) 2000-02-04 2010-11-04 ポートラ ファーマシューティカルズ, インコーポレイテッド 血小板adpレセプターインヒビター

Also Published As

Publication number Publication date
US7294635B2 (en) 2007-11-13
EP1667989A1 (en) 2006-06-14
CA2539882A1 (en) 2005-04-21
US20050113399A1 (en) 2005-05-26
EP1667989A4 (en) 2008-08-20
JP2007507519A (ja) 2007-03-29
AU2004279809A1 (en) 2005-04-21
IL174445A0 (en) 2006-08-01
AU2004279809B2 (en) 2010-07-15
MXPA06003625A (es) 2006-08-11
CN1863789B (zh) 2010-06-09
WO2005035520A1 (en) 2005-04-21
CN1863789A (zh) 2006-11-15
JP4879745B2 (ja) 2012-02-22
IL174445A (en) 2012-02-29

Similar Documents

Publication Publication Date Title
KR20060113699A (ko) 치환된 이소퀴놀리논
EP1668002B1 (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
US8680139B2 (en) Anti-neoplastic compounds, compositions and methods
CN101605779B (zh) 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物
EP2315588B1 (en) 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands
US7205296B2 (en) Substituted 2H-1,3-benzoxazin-4(3H)-ones
KR20000010905A (ko) 도파민 d3 수용체의 조절제로서의 테트라히드로이소퀴놀린유도체
EP0922035B1 (en) Tetrahydroisoquinoline derivatives and their pharmaceutical use
JPWO2006057270A1 (ja) 含窒素3環化合物
JP2005501826A (ja) 置換イソインドールおよびそれらの使用
CA2560098A1 (en) 2-aminoquinazoline derivative
CA2494616A1 (en) Furanthiazole derivatives as heparanase inhibitors
CN117800955A (zh) 2位或4位吡喃酮类衍生物及其药物组合物、制备方法和用途
CN104803914A (zh) 作为Rho激酶抑制剂的六氢氮杂卓氧基苯甲酰胺类化合物
HK1093973B (en) 2,4-dioxo-3-quinazolinylaryl sulfonylureas
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060503

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110511

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20120520

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20121105

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120520

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20110511

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I